Ionis Pharmaceuticals Inc.
(NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) on Thursday said their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint.
In patients receiving contemporary standard of care, including a majority treated with a transthyretin stabilizer, adding eplontersen did not significantly reduce the combined risk of cardiovascular mortality and recurrent cardiovascular clinical events through Week 140 versus placebo.
At baseline, 57% of participants in both treatment groups were receiving stabilizer therapy, while another 24% in each arm started a stabilizer during the study.
Read Also: Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk Subgroup Analysis And Secondary Endpoints ATTR-CM is caused by misfolded transthyretin (TTR) proteins that build up in the heart, stiffening the heart muscle, leading to heart failure.
